Valion Bio, Inc. (VBIO)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 700K 1.4M 2.1M Q4 '21: 1.3M Q1 '22: 1.4M Q2 '22: 1.6M Q3 '22: 1.8M Q4 '22: 1.8M Q1 '23: 1.8M Q2 '23: 1.4M Q3 '23: 1.2M Q4 '23: 1.2M Q1 '24: 1.1M Q2 '24: 1.1M Q3 '24: 957K Q4 '24: 780K Q1 '25: 516K Q2 '25: 462K Q3 '25: 482K Q1 '22 Q3 '22 Q1 '23 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25

Gross Profit TTM

-150K 0 150K 300K 450K Q4 '21: -39K Q1 '22: 9K Q2 '22: 167K Q3 '22: 256K Q4 '22: 301K Q1 '23: 344K Q2 '23: 280K Q3 '23: 325K Q4 '23: 287K Q1 '24: 341K Q2 '24: 310K Q3 '24: 246K Q1 '22 Q3 '22 Q1 '23 Q3 '23 Q1 '24 Q3 '24

Operating Income TTM

-18M -12M -6M 0 6M 12M 18M Q4 '21: -5.6M Q1 '22: -6.8M Q2 '22: -8.8M Q3 '22: -10.1M Q4 '22: -10.1M Q1 '23: -10M Q2 '23: -9.1M Q3 '23: -8.3M Q4 '23: -8.2M Q1 '24: -7.6M Q2 '24: -6.8M Q3 '24: -6.4M Q4 '24: -4.5M Q1 '25: -4.4M Q2 '25: -4.8M Q3 '25: -5.8M Q4 '25: -7.5M Q1 '26: -11.8M Q2 '26: -16.5M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-21M -14M -7M 0 7M 14M 21M Q4 '21: -8.5M Q1 '22: -9.4M Q2 '22: -11.3M Q3 '22: -11.6M Q4 '22: -10.1M Q1 '23: -10M Q2 '23: -9.1M Q3 '23: -8.3M Q4 '23: -8.2M Q1 '24: -7.6M Q2 '24: -6.8M Q3 '24: -6.4M Q4 '24: -5.7M Q1 '25: -5.7M Q2 '25: -6.3M Q3 '25: -7.5M Q4 '25: -8.9M Q1 '26: -13.6M Q2 '26: -18.8M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

0 600K 1.2M 1.8M Q4 '21: 1.3M Q1 '22: 1.4M Q2 '22: 1.5M Q3 '22: 1.6M Q4 '22: 1.5M Q1 '23: 1.4M Q2 '23: 1.1M Q3 '23: 902K Q4 '23: 889K Q1 '24: 793K Q2 '24: 803K Q3 '24: 711K Q4 '24: 778K Q1 '25: 631K Q2 '25: 553K Q3 '25: 762K Q1 '22 Q3 '22 Q1 '23 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25

Operating Cash Flow TTM

-15M -10M -5M 0 5M 10M 15M Q4 '21: -5.6M Q1 '22: -7.1M Q2 '22: -8.3M Q3 '22: -9.5M Q4 '22: -8.9M Q1 '23: -9.2M Q2 '23: -9.9M Q3 '23: -9M Q4 '23: -8.5M Q1 '24: -7.8M Q2 '24: -6.6M Q3 '24: -6.1M Q4 '24: -5.7M Q1 '25: -4.9M Q2 '25: -5.5M Q3 '25: -6.1M Q4 '25: -7M Q1 '26: -11.1M Q2 '26: -14.6M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-15M -10M -5M 0 5M 10M 15M Q4 '22: -8.9M Q1 '23: -9.3M Q2 '23: -10M Q3 '23: -9.1M Q4 '23: -8.6M Q3 '25: -6.1M Q4 '25: -7M Q1 '26: -11.2M Q2 '26: -14.7M Q4 '22 Q2 '23 Q4 '23 Q4 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 3.5M 7M 10.5M Q1 '21: 2.3M Q2 '21: 2.4M Q3 '21: 2.6M Q1 '22: 9.7M Q2 '22: 9.6M Q3 '22: 96.8K Q1 '23: 201.2K Q2 '23: 296.8K Q3 '23: 1.2M Q1 '24: 86.3K Q2 '24: 235.9K Q3 '24: 6.2M Q1 '25: 596.4K Q2 '25: 881.3K Q3 '25: 1.3M Q1 '26: 2.9M Q2 '26: 3.4M Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-210.00 -140.00 -70.00 0.00 70.00 140.00 210.00 Q4 '21: -2.41 Q1 '22: -2.06 Q2 '22: -1.92 Q3 '22: -28.02 Q4 '22: -50.87 Q1 '23: -61.16 Q2 '23: -68.00 Q3 '23: -42.48 Q4 '23: -185.36 Q1 '24: -191.99 Q2 '24: -190.20 Q3 '24: -188.95 Q4 '24: -41.36 Q1 '25: -26.73 Q2 '25: -23.55 Q3 '25: -25.29 Q4 '25: -8.03 Q1 '26: -7.74 Q2 '26: -7.72 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.